InflaRx NV Gets a Buy Rating from B.Riley FBR


B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on InflaRx NV (NASDAQ: IFRX) yesterday and set a price target of $43. The company’s shares closed yesterday at $29.81.

Kumar wrote:

“This morning, InflaRx (IFRX) announced approval by the FDA to start Phase II studies of lead asset, complement C5a antibody IFX-1, in ANCA-associated vasculitis (AAV). While we view expansion of the pipeline to be a positive event for IFRX, we reiterate our belief that hidradenitis suppurativa (HS) remains the key value driver for IFRX shares. We thus reiterate our IFRX Buy rating and $43 price target.”

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 33.7% and a 55.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Clementia Pharmaceuticals Inc, Deciphera Pharmaceuticals Inc, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on InflaRx NV is a Strong Buy with an average price target of $46.67, implying a 56.6% upside from current levels. In a report released yesterday, SunTrust Robinson also initiated coverage with a Buy rating on the stock with a $55 price target.

.

See today’s analyst top recommended stocks >>

Based on InflaRx NV’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $13.78 million. In comparison, last year the company had a GAAP net loss of $4.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

InflaRx NV is a biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its pipeline includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts